CRA analyzed market definition in antitrust litigation concerning a product in the non-opioid pain category. In defining the relevant antitrust market, our work accounted for indicators of competition among branded pharmaceutical products, including market positioning, factors driving physician choice, development of new approved indications, and competition for formulary listing.
How compulsory licensing shaped innovation in the Xerox case
In a new article published in the Journal of Industrial Economics, CRA’s Robin Mamrak shows that opening up an incumbent’s patent portfolio can promote...